Use of Toll-like receptor 5 (TLR5) agonist stFla in anti-pulmonary fibrosis

Abstract

The invention discloses an application of a TLR5 agonist in the preparation of pulmonary fibrosis treatment medicines, and the preferable TLR5 agonist is selected from stFla. The fibrosis which is a primary pathologic base of the disability causing and the death causing of many chronic diseases severely threatens the health and lives of people. The incidence rate and the fatality of the pulmonary fibrosis have continuously rising trends. The TLR5 agonist, preferably the TLR5 agonist selected from the stFla, disclosed in the invention can substantially reduce the mortality of bleomycin induced pulmonary fibrosis mice, activate the TLR5 signal path, substantially reduce the pulmonary inflammation reactions caused by the bleomycin, and mitigate the pulmonary tissue fibrosis degree caused by the bleomycin, comprising the pulmonary collagen deposition, the hydroxyproline content and the -SMA expression.

Description

technical field [0001] The invention designs a new application of Toll-like receptor 5 agonist stFla in treating pulmonary fibrosis, and belongs to the technical field of medicine. Background technique [0002] Abnormal tissue remodeling is the main cause of organ failure, and fibrosis, as one of the important pathological manifestations of tissue remodeling, is the main cause of disability and death in many clinical diseases today, seriously threatening people's health and life. Pulmonary fibrosis (Pulmonary fibrosis) is the main pathological change of a variety of pulmonary interstitial inflammatory diseases, including asthma, chronic bronchitis, bronchiectasis, tuberculosis, lung cancer, interstitial lung disease, etc., and its typical feature is excessive fibrosis tissue replacement Functional lung tissue, resulting in impaired lung function. In recent years, the morbidity and mortality of pulmonary fibrosis have been on the rise. For example, the average survival time...

AI Technical Summary

Problems solved by technology

Inducing factors for pulmonary fibrosis in mice include high concentrations of oxygen, asbestos, silicon dioxide, radiation, etc., but only the lung lesions induced by bleomycin have typical pathological features of interstitial pulmonary fibrosis: early diffuse alveolar Inflammation, alveolar epithelial damage, alveolar unit structure disorder, followed by a large number of interstitial cell proliferation, extracellular matrix progressive accumulation to replace the normal lung tissue structure, seriously affecting lung function

Images